United Therapeutics Corporation

Healthcare · Drug Manufacturers - Specialty & Generic

541.60$ +1.0% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Income Statement

United Therapeutics Corporation (UTHR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 783 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement UTHR
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	408	409	371	445	446	465	389	445	413	381	363	374	402	311	356	362	380	385	379	447	445	415	462	467	516	492	507	597	609	615	678	715	749	736	794	799	800	790	782	783	3,155
Cost of Revenue	24	28	14	19	20	53	53	62	52	32	29	27	33	29	23	26	24	35	23	37	28	35	26	30	37	56	52	64	70	71	73	78	83	76	93	88	101	103	133	100	437
Gross Profit	385	381	356	426	426	412	336	383	361	350	334	347	369	282	333	336	356	350	356	409	417	381	436	437	479	436	455	532	539	544	605	637	666	660	702	711	699	687	648	684	2,717
Research & Development	46	67	36	60	55	114	36	82	101	139	897	86	86	114	73	90	69	126	304	74	79	83	69	94	66	94	83	89	85	151	104	140	104	134	149	134	128	140	138	146	552
Selling, General & Administrative	80	110	41	52	31	142	20	68	110	48	78	26	85	87	80	93	54	142	104	96	92	112	65	125	81	143	70	110	107	108	121	152	199	136	144	160	154	157	155	138	604
Total Operating Expenses	146	206	93	127	102	273	29	165	211	218	989	126	185	219	166	196	135	285	421	187	188	211	148	235	165	260	170	219	212	284	249	317	323	302	319	347	309	329	322	353	1,314
Operating Income	239	174	264	89	324	139	307	217	150	132	-656	221	183	64	167	141	221	65	-65	222	229	170	288	202	314	176	284	313	327	260	356	320	343	358	383	365	389	358	326	331	1,403
Interest Expense	0.5	2.2	0.8	1.4	3.3	3.5	2.6	2.9	4.1	4.3	10	12	12	10	8.2	5.6	4.9	4.8	4.6	4.7	4.6	4.7	4.7	6.2	9.2	12	14	15	16	15	13	12	10	7.9	6.1	7.3	3.0	3.1	3.0	2.9	12
Pre-Tax Income	239	172	264	44	321	141	309	218	140	92	-651	250	167	68	172	134	219	114	33	217	204	141	309	151	313	179	292	335	352	295	399	355	389	397	424	408	438	444	318	373	1,573
Income Tax Expense	77	61	85	100	44	122	65	45	34	27	-156	45	35	16	34	27	48	16	4.2	44	42	28	69	35	73	47	51	76	84	78	92	77	80	95	101	99	99	80	43	40	262
Net Income	162	110	179	-56	276	19	245	173	107	65	-495	205	132	53	138	107	171	99	28	173	163	112	240	116	239	132	241	259	268	217	307	278	309	301	322	310	339	364	275	333	1,311
EBITDA	248	182	272	306	332	144	320	229	159	139	-630	232	196	77	179	152	233	80	50	234	221	182	326	170	335	198	319	363	381	324	427	386	418	424	437	437	463	470	344	376	1,652

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings